Timothy Wright appointed as global head of development at Novartis Pharmaceuticals
pharmafile | November 9, 2011 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing |Â Â NovartisÂ
Novartis has appointed Dr Timothy Wright as the new global head of development of its pharmaceuticals business, effective immediately.
Dr Wright joined Novartis in 2004 and most recently served as senior vice president and global head of translational sciences at Novartis Institutes for BioMedical Research (NIBR).
His group included translational medicine, biomarker development, pre-clinical safety (toxicology), and drug metabolism and pharmacokinetics.
Previously, he worked for Pfizer global research and development as the exploratory therapy area leader for inflammation.
He also served as chief of the division of rheumatology and clinical immunology, and as an endowed professor at the University of Pittsburgh.
Dr Wright received a BA in biology from the University of Delaware and a medical degree from the Johns Hopkins University School of Medicine.
Related Content

Novartis receives SMC approval for early breast cancer treatment
Novartis has announced that its treatment for early breast cancer, Kisqali (ribociclib), has received approval …

Novartis candidate for Sjögren’s disease presents positive results
Novartis has reported positive results from two phase 3 clinical trials – NEPTUNUS-1 and NEPTUNUS-2 …

First malaria medicine for infants under 4.5kg receives approval
Coartem (artemether-lumefantrine) Baby, or Riamet, has been approved by Swissmedic as the first malaria medicine …






